BioPharmSignal logoBioPharmSignal

Biotech News

Kymera Therapeutics to Report Third Quarter 2026 Financial Results on October 29, 2026

Kymera (KYMR)KymeraEarnings

Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, will report third quarter 2026 financial results on October 29, 2026. The Company will host a video conference call and webcast at 8:30 a.m. ET that day.

Related news

ARGXArgenx2026-10-15 05:00 EST

argenx to Report Third Quarter 2026 Financial Results and Business Update on October 22, 2026

NRIXNurix Therapeutics2026-10-12 20:05 EST

Nurix Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update

REGNRegeneron Pharmaceuticals2026-09-24 20:05 EST

Regeneron to Report Third Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast on October 30, 2026

REPLReplimune Group2026-10-22 12:00 EST

Replimune to Report the Fiscal Second Quarter 2027 Financial Results and Provide Corporate Update on October 28, 2026

EXELExelixis2026-10-15 20:05 EST

Exelixis to Release Third Quarter 2026 Financial Results on Thursday, October 29, 2026

RVMDRevolution Medicines2026-10-21 20:05 EST

Revolution Medicines to Report Financial Results for Third Quarter 2026 After Market Close on November 4, 2026

BNTXBioNTech2026-10-20 10:45 EST

BioNTech to Report Third Quarter 2026 Financial Results and Corporate Update on November 3, 2026

GERNGeron2026-10-21 12:00 EST

Geron Plans to Announce Third Quarter 2026 Financial Results on November 4, 2026

IMVTImmunovant2026-10-21 11:00 EST

Immunovant to Report Financial Results for the Second Fiscal Quarter Ended September 30, 2026, and Provide Business Update on Monday, November 9, 2026

FATEFate Therapeutics2026-10-01 11:00 EST

Fate Therapeutics to Participate in Upcoming Fourth Quarter 2026 Conferences

View all latest news

Kymera

Targeted Protein Degradation Kymera Therapeutics develops oral small-molecule degraders that recruit the cell’s protein-disposal machinery to remove disease-causing targets. The platform is intended to address proteins and pathways that are difficult to inhibit with conventional drugs. KT-621 KT-621 is a once-daily oral degrader of...

Recent company news

KYMRKymera2026-10-22 20:01 EST

Kymera Therapeutics to Report Third Quarter 2026 Financial Results on October 29, 2026

KYMRKymera2026-09-02 20:01 EST

Kymera Therapeutics to Participate in Upcoming September Investor Conferences

KYMRKymera2026-09-01 11:00 EST

Kymera Therapeutics Announces Presentations on KT-621, a First-in-Class, Oral STAT6 Degrader, at the European Respiratory Society and European Academy of Dermatology & Venereology Congresses

KYMRKymera2026-08-05 11:00 EST

Kymera Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business Update

KYMRKymera2026-07-28 20:01 EST

Kymera Therapeutics to Report Second Quarter 2026 Financial Results on August 5, 2026

Stock data

Close
112.63 USD
Market cap
5.86B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States